Since 1994, trials of zidovudine, zidovudine and lamivudine, and nevirapine have
demonstrated that these antiretroviral drugs can substantially reduce the risk of perinatal HIV …

Mother-to-child transmission of HIV-1 is responsible for the infection of hundreds of
thousands of infants every year. The use of prophylactic antiretroviral treatments has brought …

Background: There are limited data on primary human immunodeficiency virus drug
resistance (HIVDR) in pediatric populations. This study aimed to assess the prevalence of …

Exposure of infants to antiretroviral drugs for prevention of mother-to-child transmission can
induce resistance to nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). Data …

Background: The HIV Prevention Trials Network (HPTN) 046 trial evaluated the efficacy of
extended infant nevirapine (NVP) administration for prevention of HIV transmission through …

We analyzed the development of nevirapine (NVP) resistance in human immunodeficiency
virus type 1 (HIV-1)—infected Malawian infants who received regimens containing …

Nevirapine resistance has been detected in a considerable proportion of women after single-
dose nevirapine (SD-NVP) for the prevention of mother-to-child human immunodeficiency …

Background The presence of antiretroviral drug-associated resistance mutations (DRMs)
may be particularly problematic in human immunodeficiency virus (HIV)–infected pregnant …

Considerable advances have been made in the effort to prevent mother-to-child HIV
transmission (PMTCT) in sub-Saharan Africa. Clinical trials have demonstrated the efficacy …

Background Nevirapine and lamivudine given to mothers are transmitted to infants via
breastfeeding in quantities sufficient to have biologic effects on the virus; this may lead to an …